As we approach the end of the year, BMD Software is proud to share significant milestones for the NeoScreen ecosystem. Building on our commitment to global excellence in newborn screening, we have strengthened our presence in Spain. We have established new deployments in Madrid, Valladolid, and Oviedo. As a result, this expansion allows us to provide even closer support to our partners and further reinforces our dedication to the region.
NeoScreen v5.3.0 provides an end-to-end newborn screening workflow, enabling laboratories to seamlessly acquire samples, import data, support diagnosis, and generate reports within a single integrated platform.
Seamless Integration for Uninterrupted Workflows
At the core of our development philosophy lies close collaboration. For this reason, we have focused heavily on developing deep integrations with existing laboratory information systems. Ultimately, our goal is simple: ensure no workflow is interrupted – only improved.
Driven by User Feedback
Our development philosophy is rooted in close collaboration. Our direct contact with users provides us with invaluable feedback, which drives our rapid development cycles. This agility allows us to implement new functionalities quickly, ensuring NeoScreen constantly evolves to meet the real-world needs of screening laboratories.
A Complete, Multidisciplinary Platform
NeoScreen continues to prove itself as an extremely complete system that is easy to start using and configure. Beyond the core expertise in MS/MS mass spectrometry, the platform is fully equipped to analyze a wide spectrum of conditions, including:
- Congenital Hypothyroidism
- Cystic Fibrosis
- SCID (Severe Combined Immunodeficiency)
- Chromatography & Metabolic Diseases
Manage the Entire Sample Lifecycle
If your laboratory is searching for a complete platform to manage the entire sample lifecycle, from initial collection and administration all the way to delivering results to parents – we are ready to help.
Connect with us to learn how the NeoScreen ecosystem can transform your laboratory’s operations in 2026 and beyond.